Septerna, Inc. $SEPN Stock Position Lowered by State of Wyoming

State of Wyoming reduced its holdings in Septerna, Inc. (NASDAQ:SEPN) by 73.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,328 shares of the company’s stock after selling 12,051 shares during the period. State of Wyoming’s holdings in Septerna were worth $169,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sterling Capital Management LLC grew its stake in Septerna by 215.0% during the 3rd quarter. Sterling Capital Management LLC now owns 630 shares of the company’s stock valued at $25,000 after acquiring an additional 430 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in Septerna in the 2nd quarter worth approximately $211,000. Canada Pension Plan Investment Board purchased a new position in Septerna in the 2nd quarter worth approximately $298,000. Legal & General Group Plc acquired a new position in shares of Septerna during the 2nd quarter worth approximately $337,000. Finally, Man Group plc acquired a new position in shares of Septerna during the 2nd quarter worth approximately $384,000.

Insider Buying and Selling

In related news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total value of $149,640.00. Following the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $6,517,158.69. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Daniel D. Long sold 3,333 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the completion of the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,647,265.96. This represents a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 32,333 shares of company stock valued at $1,375,727 in the last 90 days. Insiders own 5.80% of the company’s stock.

Septerna Stock Performance

Septerna stock opened at $48.85 on Monday. The company has a 50-day moving average price of $39.52 and a 200 day moving average price of $32.59. Septerna, Inc. has a 12-month low of $17.55 and a 12-month high of $51.10. The stock has a market cap of $2.28 billion, a P/E ratio of -90.46 and a beta of 2.20.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The company had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. As a group, analysts forecast that Septerna, Inc. will post -1.41 EPS for the current year.

Wall Street Analyst Weigh In

SEPN has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Thursday, October 15th. Wells Fargo & Company lifted their price objective on Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. HC Wainwright lifted their price objective on Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Stifel Nicolaus set a $49.00 price objective on Septerna in a research note on Tuesday, August 11th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.22.

Septerna Profile

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.